This site uses cookies to bring you the best experience. Find out more
Skip to main content


Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

Contact us on if you would like to know more about any of these stories.

You can also keep up to date by following us on Twitter or LinkedIn    

Digital Catapult unveils five firms to explore potential of Open RAN technology on SONIC Labs testbed

Digital Catapult, with support from its partner Ofcom, has onboarded five companies to its SONIC Labs programme to trial the integration of Open RAN (Radio Access Network) products into working end-to-end systems Participating organisations will work collaboratively with each other, Digital Catapult and Ofcom to integrate and test their products in lab and indoor mobile network settings, accelerating their route to... Read more

Oxford Science Enterprises Raises £250 Million

New funding deepens capital pool available to drive the creation and growth of transformational businesses built on ground-breaking Oxford science Oxford, UK: July 18, 2022 – Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, today announces it has raised a further £250 million ($300... Read more

TOSP agrees to sale of development site to Lawrence J. Ellison Institute for Transformative Medicine

The Oxford Science Park agrees to sale of development site to the Lawrence J. Ellison Institute for Transformative Medicine US research organisation creates new campus to build collaborations across the Oxford life science ecosystem Oxford, UK, July 18 2022 – Leading US-based research organisation, the Lawrence J. Ellison Institute for Transformative Medicine, is significantly expanding its commitment to Oxford by establishing a major presence... Read more


MIROBIO RAISES $97 MILLION SERIES B FINANCING TO DEVELOP CHECKPOINT AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASES Financing led by Medicxi with significant participation from new and existing shareholders Lead program MB272 targeting checkpoint receptor BTLA, entering Phase I clinical trials Funds will be used to advance pipeline of immune checkpoint agonists into clinical trials in autoimmune diseases OXFORD, United Kingdom, June 29... Read more

OMass Therapeutics Wins The Oxford Science Park Innovation Award at Oxfordshire Business Awards

Oxford, United Kingdom – 20 June 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to announce that it has won the Oxford Science Park Innovation Award at the Oxfordshire Business Awards. The Oxfordshire Business Awards recognise, reward and promote the excellence of Oxfordshire-based companies. OMass Therapeutics received the Oxford... Read more